Prasugrel Tablet, Film Coated
Product Images NDC 63629-4829

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 63629-4829). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636294829)

Label for Prasugrel Tablets USP 10 mg, film-coated oral tablets supplied in a bottle of 30 tablets. The label includes the NDC 63629-4829-1, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Aurobindo Pharma Limited. It features dosage information, storage instructions, and QR codes for package insert and product identification.*

FDA Label Image

Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Prasugrel Fig1)

A line graph comparing the percentage of non-CABG-related TIMI major or minor bleeding events over time for Prasugrel and Clopidogrel. The x-axis represents days from randomization (0 to 450 days), and the y-axis shows the event percentage (0 to 5%). The graph shows a higher bleeding event rate with Prasugrel than Clopidogrel. A smaller inset graph displays a detailed view of the early phase (0 to 7 days). Numbers at risk for each drug are listed at several time points below the x-axis.*

FDA Label Image

Figure 2: Inhibition (mean±sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Prasugrel Fig2)

A line graph showing the inhibition of platelet aggregation (%) over time (hours) after administration of 20 μM ADP. The graph plots mean values with standard deviation error bars, illustrating a rapid increase in inhibition within the first few hours, followed by a plateau lasting up to 24 hours.*

FDA Label Image

Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Prasugrel Fig3)

Two line graphs comparing cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (%) over days from randomization for Prasugrel and Clopidogrel in UA/NSTEMI and STEMI patients. Each graph includes an inset showing early data (0-7 days) with p-values indicating statistical significance.*

FDA Label Image

Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Prasugrel Fig4)

A forest plot displaying baseline characteristics and corresponding hazard ratios comparing Prasugrel versus Clopidogrel across various subgroups, including age, gender, body weight, region, diabetes status, metabolic syndrome, myocardial infarction history, PCI history, CABG history, stroke history, symptom onset time, stent type, and GP IIb/IIIa inhibitor use. The plot shows point estimates with confidence intervals indicating relative effectiveness of the two drugs in each subgroup.*

FDA Label Image

Figure5 (Prasugrel Fig5)

A forest plot chart showing baseline characteristics and percent events comparing Prasugrel and Clopidogrel in various patient subsets with STEMI. It displays hazard ratios with confidence intervals for factors such as age, gender, body weight, region, diabetes status, previous cardiac events, and treatment types, indicating relative benefit between Prasugrel and Clopidogrel.*

FDA Label Image

Chemical Structure (Prasugrel Str)

Chemical structure of Prasugrel hydrochloride, showing its molecular arrangement including a fluorophenyl group, a thienopyridine core, and ester functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.